The influence of the CYP2C19 metabolizer phenotype was investigated by Zhou et al., who described no association between CYP2C19 activity and BTZ efficacy or the incidence of peripheral neuropathy [22]. Here, CYP2C19 is linked to peripheral neuropathy.